摘要:
The present invention provides amphiphilic compounds with a tetradecahydrophenanthrene skeleton of formula (I), wherein R1-R5 are as defined herein, and their enantiomers, exhibiting neuroprotective effects, for use as medicaments for treating neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain , addiction, multiple sclerosis, epilepsy, glioma, and a pharmaceutical composition containing said compound.
摘要:
A novel compound represented by the general formula (I), and a nematic liquid crystal composition incorporating the same. A compound represented by the general formula (I) can be produced industrially extremely easily, as shown in the examples, displays superior compatibility with current general purpose host liquid crystals as a nematic phase, and also shows little crystal precipitation at low temperatures. Moreover, by addition of a small amount of such a compound to a host liquid crystal, the liquid crystal temperature range at low temperatures can be effectively widened without any significant worsening of the various characteristics of the liquid crystal material. Consequently, a compound of the present invention is an extremely useful liquid crystal material which is suitable for various liquid crystal display elements which require a broad operating temperature range.
摘要:
Compounds are disclosed that have the chemical structure of Formula (II) and (IIB) and their produg esters and acid-addition salts, and that are useful as Interleukin-1 and Tumor Necrosis Factor-a modulators, and thus are useful in the treatment of various diseases, wherein the R groups are defined in the claims.
摘要:
The OHP content of an OHP- and THP-containing solvent is enriched by contacting the solvent with hydrogen in the presence of a supported catalyst (68) comprising Group VIB and Group VIII metals under conditions to increase the OHP/THP ratio in the solvent to a level greater than 0.4 and preferably greater than 1. The preferred catalyst contains tungsten where it is desired to provide an OHP/THP ratio greater than 1 in the OHP-enriched solvent, and also contains titanium to improve the hydrogen selectivity of the catalyst so as to enhance the preservation of aromatics in the hydrogenated solvent. The OHP-enriched solvent provides increased solvation of coal and improved yields of liquid fuel product in a coal liquefaction process which utilizes the solvent.
摘要:
The present disclosure relates to a small molecule inhibitor of cathepsin C and the medicinal use thereof. Specifically, provided in the present disclosure are an amide nitrile compound represented by formula VI, a pharmaceutical composition containing the compound, and the use thereof in the inhibition of cathepsin C.
摘要:
A novel compound represented by general formula (I) and a nematic liquid crystal composition containing the same. A compound represented by general formula (I) can be produced with great ease as is shown in an example and has excellent compatibility with a mother liquid crystal of general use being currently used as a nematic liquid crystal, and further shows reduced precipitation at a low temperature. Moreover, the addition of only a small amount of the above compound to the mother liquid crystal results in expanding effectively the temperature range for liquid crystallinity, without detriment to various properties as a liquid crystal material. Accordingly, the above compound is suitable for use in various liquid crystal display elements which are required to have a wide range of working temperature and is greatly useful as a liquid crystal material.
摘要:
A compound having the following chemical structure: its produg esters and acid-addition salts, useful as Interleukin-1 and Tumor Necrosis Factor-α modulators, wherein R groups are defined in the claims.